These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 24290498)

  • 1. Long-term effects of dalfampridine in patients with multiple sclerosis.
    Ruck T; Bittner S; Simon OJ; Göbel K; Wiendl H; Schilling M; Meuth SG
    J Neurol Sci; 2014 Feb; 337(1-2):18-24. PubMed ID: 24290498
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dalfampridine improves walking speed, walking endurance, and community participation in veterans with multiple sclerosis: a longitudinal cohort study.
    Cameron MH; Fitzpatrick M; Overs S; Murchison C; Manning J; Whitham R
    Mult Scler; 2014 May; 20(6):733-8. PubMed ID: 24099749
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase 3 trial of extended release oral dalfampridine in multiple sclerosis.
    Goodman AD; Brown TR; Edwards KR; Krupp LB; Schapiro RT; Cohen R; Marinucci LN; Blight AR;
    Ann Neurol; 2010 Oct; 68(4):494-502. PubMed ID: 20976768
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term safety and efficacy of dalfampridine for walking impairment in patients with multiple sclerosis: Results of open-label extensions of two Phase 3 clinical trials.
    Goodman AD; Bethoux F; Brown TR; Schapiro RT; Cohen R; Marinucci LN; Henney HR; Blight AR;
    Mult Scler; 2015 Sep; 21(10):1322-31. PubMed ID: 25583832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of dalfampridine, a novel pharmacologic approach for treating walking impairment in multiple sclerosis.
    Blight AR; Henney HR; Cohen R
    Ann N Y Acad Sci; 2014 Nov; 1329():33-44. PubMed ID: 25154911
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early effect of dalfampridine in patients with MS: A multi-instrumental approach to better investigate responsiveness.
    Brambilla L; Rossi Sebastiano D; Aquino D; Torri Clerici V; Brenna G; Moscatelli M; Frangiamore R; Giovannetti AM; Antozzi C; Mantegazza R; Franceschetti S; Bruzzone MG; Erbetta A; Confalonieri P
    J Neurol Sci; 2016 Sep; 368():402-7. PubMed ID: 27538672
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of dalfampridine on multi-dimensional aspects of gait and dexterity in multiple sclerosis among timed walk responders and non-responders.
    Lo AC; Ruiz JA; Koenig CM; Anderson BM; Olson KM; Triche EW
    J Neurol Sci; 2015 Sep; 356(1-2):77-82. PubMed ID: 26139339
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in Cognitive Processing Speed, Mood, and Fatigue in an Observational Study of Persons With Multiple Sclerosis Treated With Dalfampridine-ER.
    Triche EW; Ruiz JA; Olson KM; Lo AC
    Clin Neuropharmacol; 2016; 39(2):73-80. PubMed ID: 26818040
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Short-term impact of fampridine on motor and cognitive functions, mood and quality of life among multiple sclerosis patients.
    Pavsic K; Pelicon K; Ledinek AH; Sega S
    Clin Neurol Neurosurg; 2015 Dec; 139():35-40. PubMed ID: 26363365
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical overview of dalfampridine: an agent with a novel mechanism of action to help with gait disturbances.
    Egeberg MD; Oh CY; Bainbridge JL
    Clin Ther; 2012 Nov; 34(11):2185-94. PubMed ID: 23123001
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dalfampridine effects on cognition, fatigue, and dexterity.
    Korsen M; Kunz R; Schminke U; Runge U; Kohlmann T; Dressel A
    Brain Behav; 2017 Jan; 7(1):e00559. PubMed ID: 28127507
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessing dalfampridine efficacy in the physician's office.
    Raffel JB; Malik O; Nicholas RS
    Mult Scler; 2014 Jan; 20(1):24-6. PubMed ID: 23727943
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dalfampridine: a brief review of its mechanism of action and efficacy as a treatment to improve walking in patients with multiple sclerosis.
    Dunn J; Blight A
    Curr Med Res Opin; 2011 Jul; 27(7):1415-23. PubMed ID: 21595605
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The safety profile of dalfampridine extended release in multiple sclerosis clinical trials.
    Cornblath DR; Bienen EJ; Blight AR
    Clin Ther; 2012 May; 34(5):1056-69. PubMed ID: 22497693
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Estimation of the effect of dalfampridine-ER on health utility by mapping the MSWS-12 to the EQ-5D in multiple sclerosis patients.
    Limone BL; Sidovar MF; Coleman CI
    Health Qual Life Outcomes; 2013 Jun; 11():105. PubMed ID: 23799913
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dalfampridine: a medication to improve walking in patients with multiple sclerosis.
    Pikoulas TE; Fuller MA
    Ann Pharmacother; 2012; 46(7-8):1010-5. PubMed ID: 22764324
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacology and clinical efficacy of dalfampridine for treating multiple sclerosis.
    Lugaresi A
    Expert Opin Drug Metab Toxicol; 2015 Feb; 11(2):295-306. PubMed ID: 25510833
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of dalfampridine on information processing speed impairment in multiple sclerosis.
    De Giglio L; De Luca F; Gurreri F; Ferrante I; Prosperini L; Borriello G; Quartuccio E; Gasperini C; Pozzilli C
    Neurology; 2019 Aug; 93(8):e733-e746. PubMed ID: 31331968
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dalfampridine extended release: in multiple sclerosis.
    Chwieduk CM; Keating GM
    CNS Drugs; 2010 Oct; 24(10):883-91. PubMed ID: 20839898
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of Dalfampridine Extended-release Tablets on 6-minute Walk Distance in Patients With Multiple Sclerosis: A Post Hoc Analysis of a Double-blind, Placebo-controlled Trial.
    Applebee A; Goodman AD; Mayadev AS; Bethoux F; Goldman MD; Klingler M; Blight AR; Carrazana EJ
    Clin Ther; 2015 Dec; 37(12):2780-7. PubMed ID: 26565077
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.